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SUMMARY 
Tourette syndrome (TS) is a model neuropsychiatric disorder thought to arise from abnormal 
development and/or maintenance of cortico-striato-thalamo-cortical circuits. TS is highly heritable, but its 
underlying genetic causes are still elusive, and no genome-wide significant loci have been discovered to 
date. We analyzed a European ancestry sample of 2,434 TS cases and 4,093 ancestry-matched controls 
for rare (<1% frequency) copy-number variants (CNVs) using SNP microarray data. We observed a 
global enrichment of TS-associated CNVs that was most prominent in large (>1 Mb), singleton events 
(OR=3.0, 95%CI [1.4-6.6], p=5.0x10-3). We also identified two individual, genome-wide significant loci, 
each conferring a substantial increase in TS risk (NRXN1 deletions, OR=20.3, 95%CI [2.6-156.2]; 
CNTN6 duplications, OR=10.1, 95% CI [2.3-45.4]). Approximately 1% of TS cases carry one of these 
CNVs, indicating that rare structural variation contributes significantly to the genetic architecture of TS. 
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INTRODUCTION
Tourette syndrome (TS) is a complex neuropsychiatric disorder characterized by multiple chronic 
involuntary motor and vocal tics, with an estimated population prevalence of 0.3-0.9% (Scharf et al., 
2015). Tics typically emerge during childhood and peak in adolescence, with a subsequent reduction in 
symptoms, supporting the notion that TS is neurodevelopmental in origin (Robertson et al., 2017). Most 
TS patients (>85%) present with additional neuropsychiatric co-morbidities, typically attention deficit 
hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) (Hirschtritt et al., 2015), 
although the risk for mood, anxiety, major depressive, and autism spectrum disorders (ASD) is also 
elevated (Burd et al., 2009; Hirschtritt et al., 2015). Consequently, TS is often considered a model 
neuropsychiatric disorder in that identification of its underlying molecular, cellular, and neurophysiologic 
etiology may be broadly applicable to a wide range of psychiatric disorders. 
Neuroimaging (Greene et al., 2016; Marsh et al., 2009) and neurophysiology (Draper et al., 2014; 
Gilbert et al., 2004) studies suggest that TS and its associated comorbidities (e.g., OCD and ADHD) 
arise from dysregulated development and/or maintenance of parallel cortico-striatal-thalamo-cortical 
(CSTC) motor, limbic, and cognitive circuits (Jahanshahi et al., 2015). Though non-genetic factors have 
been associated with increased TS risk (Browne et al., 2016; Leivonen et al., 2016), TS is primarily a 
genetic disorder. Family studies indicate that children of affected parents have a 60-fold higher risk of 
developing TS or chronic tics (CT), a closely related disorder, compared to the general population 
(Browne et al., 2015). TS heritability is estimated to be 0.77 (Mataix-Cols et al., 2015), making it one of 
the most heritable complex neuropsychiatric disorders. Despite this strong genetic component, the 
identification of bona-fide TS susceptibility genes has proven challenging. Although linkage analyses 
have identified several candidate regions, there is little consensus across studies, suggesting that, as 
with other neuropsychiatric disorders, TS is genetically complex and heterogeneous (Robertson et al., 
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2017). Similarly, analyses of TS genetic architecture using aggregated SNP data demonstrates that TS is 
highly polygenic, with the majority of inherited TS risk distributed throughout the genome (Davis et al., 
2013), though an  initial genome-wide association study (GWAS) did not yield any genome-wide 
significant loci, likely due to small sample size (Scharf et al., 2013).  
Studies examining rare structural variation in individuals with TS have implicated several 
neurodevelopmental genes involved in neurite outgrowth and axonal migration. Rare chromosomal 
abnormalities affecting CNTNAP2 (Verkerk et al., 2003) and SLITRK1 (Abelson et al., 2005) have been 
found in isolated TS families, and exonic copy-number variants (CNVs) in NRXN1 are reported in small 
genome-wide studies (Nag et al., 2013; Sundaram et al., 2010), though no locus has yet survived 
genome-wide correction for multiple testing. Because of the evidence suggesting that rare CNVs may 
have a role in TS etiology (Fernandez et al., 2012; McGrath et al., 2014), and since such variants 
contribute to susceptibility for other heritable neurodevelopmental disorders (NDDs) (Malhotra and 
Sebat, 2012), we assessed the impact of rare CNVs on TS disease risk in a large sample of 6,527 
unrelated individuals of European ancestry. We demonstrate a global increase in the burden of large, 
rare CNVs in TS cases compared to controls driven primarily by large, singleton events, in particular 
large (>1Mb) deletions, consistent with marked genetic heterogeneity. We also report the first two TS 
susceptibility loci that meet genome-wide significance: deletions in NRXN1 and duplications in CNTN6. 
Each confers a substantial increase in disease risk and together are present in 1% of TS cases.   
RESULTS 
An overview of the sample selection, quality control, CNV detection, and data analysis performed 
in this study is presented in Figure 1 and described in detail in the STAR methods. All TS cases and 
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controls were recruited through the Tourette Syndrome Association International Consortium for 
Genetics (TSAICG) or through the Gilles de la Tourette Syndrome GWAS Replication Initiative (GGRI), 
with additional controls selected from external studies. All DNA samples were genotyped on the Illumina 
OmniExpress SNP array platform (Table S1A).  We restricted analysis to SNP assays common to all 
array versions. We conducted extensive quality control analyses including both SNP-based and CNV-
based exclusion of outliers (Table S1B and STAR Methods) and genotype-based determination of 
ancestry (Figure S1). The final dataset consisted of 6,527 unrelated European ancestry samples: 2,434 
individuals diagnosed with TS and 4,093 unselected controls. 
Genome-wide detection of CNVs was performed using the consensus of two widely-used Hidden 
Markov Model (HMM)-based methods (STAR Methods). Additionally, we used a locus-specific, intensity-
based clustering method to generate CNV genotypes in all samples across 11 common HapMap3 loci 
(Figure S2, Tables S2) for sensitivity analysis. Using the proportion of concordant HMM-based calls at 
these loci as a sensitivity measure, we confirmed the absence of any bias in CNV detection between 
cases and controls across all loci (p=0.54, Fisher’s Exact test, Tables S3A and S3B) and between 
individuals (p=0.15, Welch’s t-test, Table S3C, and STAR Methods). Post-call cleaning was performed 
(STAR Methods), and CNVs were annotated for genic content and frequency. CNVs were considered 
“genic” if they overlapped the exon of a known protein-coding Refseq transcript. Frequencies were 
defined based on a 50% overlap with other CNVs as described (CNV and SCZ Working Groups of the 
PGC, 2017); “singletons” denote CNVs with a frequency of one across the entire dataset. We filtered 
calls for rare (frequency < 1% or < 65 events) CNVs ≥30kb in length and spanning at least 10 probes. 
Finally, using a heuristically derived series of in silico validation metrics, we removed aberrant CNV calls 
due to mosaicism and misclassified rare events (Figure S4). In total, we resolved 9,375 rare CNV calls 
(Table S4). 
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Global burden analysis of rare CNVs in TS
An increase in rare CNV burden has been consistently demonstrated in other NDDs (CNV and 
Schizophrenia Working Groups of the Psychiatric Genomics Consortium and Psychosis Endophenotypes 
International Consortium, 2017). To control for potential confounders, burden analysis was performed 
using multiple logistic regression (STAR Methods) and three different standardized burden metrics: 1) 
total number of CNVs (CNV count), 2) total genomic size of all CNVs (CNV length), and 3) number of 
genes affected (CNV gene count). For genic CNVs (n=4,604), we observed a modest but significantly 
increased CNV burden across all metrics (Figure 2A): CNV count (OR 1.05 [1.01-1.10], p=0.027), CNV 
gene count (OR 1.09 [1.01-1.17], p=0.019), and CNV length (OR 1.15 [1.07-1.24], p=1.9x10-4). By 
contrast, no enrichment was seen in a comparable number (n=4,771) of non-genic events. The 
increased burden in TS was most significant for CNV length and consistent across each control set 
individually (Figure S4). To explore the CNV length burden further, we partitioned the data across a 
range of CNV size and frequency bins and observed the enrichment was mainly attributable to large 
(>1Mb; OR 1.26 [1.08-1.49], p=5.3x10-3) (Figure 2B) and/or singleton CNVs (OR 1.13 [1.04-1.24], 
p=2.9x10-3) (Figure 2C). 
Enrichment of large, singleton events and clinically relevant CNVs 
We next explored whether specific CNV classes were enriched in TS. Since the elevated TS CNV 
burden was confined to large and/or very rare events, we re-evaluated the CNV count burden restricted 
to singletons, stratified by CNV size. We observed a significant enrichment of singletons >500kb (OR 
1.43 [1.07-1.93], p=0.010) that was further increased in the largest size category (>1Mb, OR 2.28 [1.39-
3.79], p=1.2x10-3), with greater enrichment for deletions >1Mb (OR 2.75 [1.28-5.23], p=6.5x10-3) than 
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duplications (OR 1.98 [1.04-3.83], p=0.038) (Figure 3A). Notably, this enrichment was driven by CNVs 
spanning genes under strong evolutionary constraint (probability of Loss-of-Function Intolerance (pLI) 
score>0.9; Lek et al., 2015) (RR=2.65 [1.40-5.00], p=2.7x10-3; Poisson regression controlling for sex, 
CNV quality score, and ancestry principal components; STAR Methods).
It is well established that certain regions of the human genome are prone to large, rare, recurrent 
CNVs associated with a broad range of NDDs (Malhotra and Sebat, 2012). To characterize the extent to 
which these known pathogenic CNVs might also confer risk for TS, we classified all rare CNV calls by 
clinical relevance according to American College of Medical Genetics (ACMG) guidelines (Kearney et al., 
2011) and assessed for enrichment between cases and controls. Known pathogenic CNVs were 
identified in 1.9% of TS cases vs. 0.8% of controls (OR 3.03 [1.85-5.07], p=1.5x10-5) (Figure 3B). 
Consistent with an increased pathogenicity of deletions compared to duplications, this enrichment was 
greater for deletions alone (OR per CNV 3.94 [1.83-8.95], p=6.3 x10-4). By contrast, no increase in 
burden was observed among CNVs classified by the ACMG as either benign or of unknown significance. 
Deletions in NRXN1 and duplications in CNTN6 confer substantial risk for TS
To test our sample for enrichment of rare CNVs at individual genomic loci, we conducted an 
unbiased, point-wise (segmental) genome-wide association test, treating deletions and duplications 
independently (STAR Methods). As non-overlapping CNVs affecting the same gene would be 
unaccounted for by segmental assessments of enrichment, we also performed a complementary gene-
based test, conditioned on CNVs affecting exons. In contrast to SNP-based association studies, there is 
no established p-value threshold to indicate genome-wide significance for CNVs, as the number of rare 
CNV breakpoints per genome varies across individuals and detection platforms. Therefore, for both tests, 
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we established both locus-specific p-values (Pseg and Pgene for segmental and gene-based tests, 
respectively) and genome-wide corrected (Pcorr) p-values empirically through 1,000,000 label-swapping 
permutations, using the max(T) method (Westfall and Troendle, 2008) to control for familywise error rate 
(FWER). Both tests converged on the same two loci, one for deletions and another for duplications, 
which were enriched among TS cases and survived genome-wide correction for multiple testing. 
For deletions, the peak segmental association signal was located on chromosome 2p16 
(Pseg=7.0x10
-6; Pseg-corr=1.0x10
-3; Figure 4A), corresponding to heterozygous losses across the first two 
exons of NRXN1, and found exclusively among TS cases (N=10, Figure 4B). In the gene-based test of 
exonic CNVs, heterozygous NRXN1 deletions were also the most significant association genome-wide 
(Pgene=5.9x10
-5; Pgene-corr=8.5x10
-4), representing 12 cases (0.49%) and one control (0.02%), and 
corresponding to a substantially increased TS risk (OR 20.3 [2.6-156.2]). Consistent with previously 
identified pathogenic NRXN1 deletions in ASD, SCZ, and epilepsy, these exon-spanning CNVs clustered 
at the 5’ end of NRXN1 and predominantly affected the NRXN1-ɑ isoform (Ching et al., 2010). 
The segmental association test for CNV duplications identified one genome-wide significant locus 
on chromosome 3p26 within CNTN6 (Pseg=5.4x10
-5, Pseg-corr=6.9x10
-3) with a secondary peak located 
directly upstream (Pseg=5.9x10
-5,Pseg-corr=6.9x10
-3, Figures 4A and 4C). Closer inspection revealed an 
enrichment of large duplications spanning this gene. The gene-based test identified the same locus, 
exonic CNTN6 duplications, with heterozygous gains found in 12 cases (0.49%) and 2 controls (0.05%), 
corresponding to an OR=10.1 [2.3-45.4] (Pgene=2.5x10
-4, Pgene-corr =8.3x10
-3). Notably, the CNTN6
duplications in TS cases were considerably larger than those in controls (641 vs. 143 kb). 9 of 12 TS 
carriers harbored a duplication >500 kb in length, while CNTN6 duplications in controls were <200kb. 
We verified all genic CNV calls across NRXN1 and CNTN6 by inspection of probe-level intensity 
plots (Figures S5 and S6). No additional loci were significant after controlling for FWER, under either 
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segmental or gene-based tests of association, and we obtained similar results after pair-matching each 
case with its closest ancestrally matched control, suggesting that these results are not due to inter-
European population stratification (STAR Methods and Figure S7).  
DISCUSSION 
In this study, we demonstrate a significant role for rare structural variation in the pathogenesis of 
TS, a still poorly understood neurodevelopmental disorder. We observe an increased global burden of 
rare CNVs and report two definitive TS risk loci that surpass empirical thresholds for genome-wide 
significance, deletions in NRXN1 and duplications in CNTN6.
NRXN1 is a highly-studied, pre-synaptic cell-adhesion molecule involved in synaptogenesis and 
synaptic transmission at both glutamatergic and GABAergic synapses (Pak et al., 2015). The NRXN1
gene is primarily transcribed from two alternative promoters, resulting in a full-length NRXN1-α isoform 
and a short C-terminal NRXN1-β isoform (Ushkaryov et al., 1992). NRXN1-α contains six alternative 
splice sites which, in combination, generate hundreds of unique transcripts that segregate within specific 
brain regions and cell types (Fuccillo et al., 2015; Schreiner et al., 2014). NRXN1-α isoforms 
preferentially bind to various trans-synaptic partners, including neuroligins, cerebellins, neurexophilins 
and LRRTMs, each of which subserves different synaptic functions (de Wit and Ghosh, 2016). NRXN1-α
trans-synaptic interactions play a critical role in thalamo-cortical synaptogenesis and plasticity (Singh et 
al., 2016), suggesting one possible mechanism in support of the prevailing theory that TS arises from 
abnormal sensorimotor CSTC circuit development (Jahanshahi et al., 2015). 
Although previous studies have observed heterozygous exonic NRXN1 deletions in TS patients 
(Fernandez et al., 2012; Nag et al., 2013; Sundaram et al., 2010), small sample sizes precluded a 
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definitive association of this deletion with TS. We demonstrate, in a large independent sample, that 
exonic deletions affecting NRXN1 confer a substantial increase in TS risk. The association of 
heterozygous NRXN1 deletions with different NDDs is one of the most reliable findings in the 
neuropsychiatry CNV literature (Lowther et al., 2017). Consistent with this, 4 of the 12 TS cases with 
exonic NRXN1 deletions in our sample had another broadly-defined NDD (2 ASD, 1 DD, 1 
Developmental Speech/Language Disorder unspecified) (Table S5), supporting the hypothesis that these 
deletions may interfere with a generalized neurodevelopmental process which, when combined with 
other disease-specific mutations and/or background polygenic risk, results in the observed phenotypic 
pleiotropy.   
Like NRXN1, CNTN6 encodes a cell-adhesion molecule expressed primarily in the central 
nervous system (Ogawa et al., 1996). Contactins are members of the L1 immunoglobulin (Ig) superfamily 
of proteins, and Cntn6 has multiple functions in the developing mouse nervous system, including 
orientation of apical dendrites in cortical pyramidal neurons (Ye et al., 2008), regulation of Purkinje cell 
development and synaptogenesis (Sakurai et al., 2009), and oligodendrocyte differentiation from 
neuroprogenitor cells (Cui et al., 2004). Mice with homozygous inactivation of Cntn6 display delayed 
corticospinal tract formation and motor impairment (Huang et al., 2012).  
Duplications in CNTN6 represent a novel association for TS. CNVs affecting CNTN6 have been 
reported in isolated cases of intellectual disability/developmental delay (ID/DD) (Kashevarova et al., 
2014), and deletions alone are enriched in ASD (Mercati et al., 2016). Notably, in a clinical series of 
3,724 patients referred for cytogenetic testing, all 7 CNTN6 duplication carriers either presented with or 
had a first-degree relative with ADHD and/or OCD, while none of the 7 CNTN6 deletion carriers were 
diagnosed with these two common TS comorbidities (Hu et al., 2015). In our study, the rates of co-
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morbid OCD/ADHD were not increased in TS CNTN6 CNV carriers compared to non-carriers, and no TS 
CNTN6 carrier was noted to have ASD/ID/DD (Table S5).  
There are several limitations of the current study that can inform future inquiry. First, although our 
sample represents the largest survey of CNVs in TS to date (2,434 cases and 4,093 controls), it is still 
underpowered to detect extremely rare CNVs and/or those of moderate effect size. Although we show 
strong evidence for the involvement of deletions across NRXN1, our data does not support other 
previously implicated loci, including deletions in COL8A1 (Nag et al., 2013), observed only once in a 
single TS patient in this study. While a nominal enrichment of COL8A1 deletions in TS was originally 
described in a South American population isolate and possibly represents a population-specific TS risk 
factor, we emphasize the need for further increases in sample size for continued discovery and 
refinement of candidate TS loci. Second, while our TS cases were well characterized for OCD and 
ADHD, we did not formally assess ASD, ID, SCZ or epilepsy. Parents and/or adult subjects were queried 
about existing diagnoses of these NDDs as well as learning disorders/developmental delay, but cases 
with milder ASD/DD may not have been detected. Additional efforts should focus on characterizing the 
full scope of phenotypes associated with NRXN1 and CNTN6 CNVs. A comprehensive molecular 
analysis of these CNVs, including the precise delineation of CNV breakpoints using an auxiliary 
technology and evaluation of their impact on gene function, will also be needed to understand how these 
variants increase risk for such phenotype(s). Finally, the elevated burden observed here was largely 
confined to large singletons and known pathogenic CNVs, consistent with a global enrichment of CNVs 
under strong negative selection that likely arose de novo or within the last few generations. This 
suggests that, in addition to substantial increases in sample size, alternative study designs that allow for 
the discrimination of de novo CNVs will be fruitful in TS, as has recently been shown for likely-gene-
disrupting variants identified by exome sequencing in TS trios (WIllsey et al., 2017). 
14 
AUTHOR CONTRIBUTIONS 
All authors were involved in the conception and design of this study. A.H., P.P., C.A.M., J.M.S., and G.C. 
designed and oversaw the analyses. A.H., D.Y., L.K.D., J.H.S., F.T., V.R., I.Z., E.M.R., L.O., J.A.C., 
L.M.M., B.M.N., N.B.F., P.P., C.A.M., J.M.S., and G.C. conducted the analyses. Major contributions to 
writing and editing were made by A.H., C.A.M., J.M.S, and G.C. All authors assisted with critically 
revising the manuscript. 
ACKNOWLEDGMENTS 
The authors thank the patients with Tourette Syndrome and their families, and all the volunteers who 
participated in this study. This study was supported by the US NIH U01 NS040024 to Drs. Pauls, 
Mathews, and Scharf and the TSAICG, ARRA Grant NS040024-09S1, K23 MH085057, and K02 
NS085048 to Dr. Scharf, ARRA Grants NS040024-07S1 and NS016648 to Dr. Pauls, MH096767 to Dr. 
Mathews and NINDS Informatics Center for Neurogenetics and Neurogenomics grant P30 NS062691 to 
Drs. Coppola and Freimer, by grants from the Tourette Association of America to Drs. Paschou, Pauls, 
Mathews, and Scharf and from the German Research Society to Dr. Hebebrand. 
15 
WORKS CITED 
Abelson, J.F., Kwan, K.Y., O’Roak, B.J., Baek, D.Y., Stillman, A.A., Morgan, T.M., Mathews, C.A., Pauls, 
D.L., Rasin, M.-R., Gunel, M., et al. (2005). Sequence variants in SLITRK1 are associated with 
Tourette’s syndrome. Science 310, 317–320.
Browne, H.A., Hansen, S.N., Buxbaum, J.D., Gair, S.L., Nissen, J.B., Nikolajsen, K.H., Schendel, D.E., 
Reichenberg, A., Parner, E.T., and Grice, D.E. (2015). Familial clustering of tic disorders and obsessive-
compulsive disorder. JAMA Psychiatry 72, 359–366.
Browne, H.A., Modabbernia, A., Buxbaum, J.D., Hansen, S.N., Schendel, D.E., Parner, E.T., 
Reichenberg, A., and Grice, D.E. (2016). Prenatal Maternal Smoking and Increased Risk for Tourette 
Syndrome and Chronic Tic Disorders. J. Am. Acad. Child Adolesc. Psychiatry 55, 784–791.
Burd, L., Li, Q., Kerbeshian, J., Klug, M.G., and Freeman, R.D. (2009). Tourette syndrome and comorbid 
pervasive developmental disorders. J. Child Neurol. 24, 170–175.
Ching, M.S.L., Shen, Y., Tan, W.-H., Jeste, S.S., Morrow, E.M., Chen, X., Mukaddes, N.M., Yoo, S.-Y., 
Hanson, E., Hundley, R., et al. (2010). Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum 
of developmental disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 937–947.
CNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium, and Psychosis 
Endophenotypes International Consortium (2017). Contribution of copy number variants to schizophrenia 
from a genome-wide study of 41,321 subjects. Nat. Genet. 49, 27–35.
Cui, X.-Y., Hu, Q.-D., Tekaya, M., Shimoda, Y., Ang, B.-T., Nie, D.-Y., Sun, L., Hu, W.-P., Karsak, M., 
Duka, T., et al. (2004). NB-3/Notch1 pathway via Deltex1 promotes neural progenitor cell differentiation 
into oligodendrocytes. J. Biol. Chem. 279, 25858–25865.
Davis, L.K., Yu, D., Keenan, C.L., Gamazon, E.R., Konkashbaev, A.I., Derks, E.M., Neale, B.M., Yang, 
J., Lee, S.H., Evans, P., et al. (2013). Partitioning the heritability of Tourette syndrome and obsessive 
compulsive disorder reveals differences in genetic architecture. PLoS Genet. 9, e1003864.
Draper, A., Stephenson, M.C., Jackson, G.M., Pépés, S., Morgan, P.S., Morris, P.G., and Jackson, S.R. 
(2014). Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome. 
Curr. Biol. 24, 2343–2347.
Fernandez, T.V., Sanders, S.J., Yurkiewicz, I.R., Ercan-Sencicek, A.G., Kim, Y.-S., Fishman, D.O., 
Raubeson, M.J., Song, Y., Yasuno, K., Ho, W.S.C., et al. (2012). Rare copy number variants in tourette 
syndrome disrupt genes in histaminergic pathways and overlap with autism. Biol. Psychiatry 71, 392–
402.
Fuccillo, M.V., Földy, C., Gökce, Ö., Rothwell, P.E., Sun, G.L., Malenka, R.C., and Südhof, T.C. (2015). 
Single-Cell mRNA Profiling Reveals Cell-Type-Specific Expression of Neurexin Isoforms. Neuron 87, 
326–340.
Gilbert, D.L., Bansal, A.S., Sethuraman, G., Sallee, F.R., Zhang, J., Lipps, T., and Wassermann, E.M. 
(2004). Association of cortical disinhibition with tic, ADHD, and OCD severity in Tourette syndrome. Mov. 
16 
Disord. 19, 416–425.
Greene, D.J., Williams, A.C., Iii, Koller, J.M., Schlaggar, B.L., and Black, K.J. (2016). Brain structure in 
pediatric Tourette syndrome. Mol. Psychiatry.
Hirschtritt, M.E., Lee, P.C., Pauls, D.L., Dion, Y., Grados, M.A., Illmann, C., King, R.A., Sandor, P., 
McMahon, W.M., Lyon, G.J., et al. (2015). Lifetime prevalence, age of risk, and genetic relationships of 
comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiatry 72, 325–333.
Hu, J., Liao, J., Sathanoori, M., Kochmar, S., Sebastian, J., Yatsenko, S.A., and Surti, U. (2015). CNTN6 
copy number variations in 14 patients: a possible candidate gene for neurodevelopmental and 
neuropsychiatric disorders. J. Neurodev. Disord. 7, 26.
Huang, Z., Yu, Y., Shimoda, Y., Watanabe, K., and Liu, Y. (2012). Loss of neural recognition molecule 
NB-3 delays the normal projection and terminal branching of developing corticospinal tract axons in the 
mouse. J. Comp. Neurol. 520, 1227–1245.
Jahanshahi, M., Obeso, I., Rothwell, J.C., and Obeso, J.A. (2015). A fronto-striato-subthalamic-pallidal 
network for goal-directed and habitual inhibition. Nat. Rev. Neurosci. 16, 719–732.
Kashevarova, A.A., Nazarenko, L.P., Schultz-Pedersen, S., Skryabin, N.A., Salyukova, O.A., 
Chechetkina, N.N., Tolmacheva, E.N., Rudko, A.A., Magini, P., Graziano, C., et al. (2014). Single gene 
microdeletions and microduplication of 3p26.3 in three unrelated families: CNTN6 as a new candidate 
gene for intellectual disability. Mol. Cytogenet. 7, 97.
Kearney, H.M., Thorland, E.C., Brown, K.K., Quintero-Rivera, F., South, S.T., and Working Group of the 
American College of Medical Genetics Laboratory Quality Assurance Committee (2011). American 
College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal 
constitutional copy number variants. Genet. Med. 13, 680–685.
Leivonen, S., Voutilainen, A., Chudal, R., Suominen, A., Gissler, M., and Sourander, A. (2016). Obstetric 
and Neonatal Adversities, Parity, and Tourette Syndrome: A Nationwide Registry. J. Pediatr. 171, 213–
219.
Lowther, C., Speevak, M., Armour, C.M., Goh, E.S., Graham, G.E., Li, C., Zeesman, S., Nowaczyk, 
M.J.M., Schultz, L.-A., Morra, A., et al. (2017). Molecular characterization of NRXN1 deletions from 
19,263 clinical microarray cases identifies exons important for neurodevelopmental disease expression. 
Genet. Med. 19, 53–61.
Malhotra, D., and Sebat, J. (2012). CNVs: harbingers of a rare variant revolution in psychiatric genetics. 
Cell 148, 1223–1241.
Marsh, R., Maia, T.V., and Peterson, B.S. (2009). Functional disturbances within frontostriatal circuits 
across multiple childhood psychopathologies. Am. J. Psychiatry 166, 664–674.
Mataix-Cols, D., Isomura, K., Pérez-Vigil, A., Chang, Z., Rück, C., Larsson, K.J., Leckman, J.F., 
Serlachius, E., Larsson, H., and Lichtenstein, P. (2015). Familial Risks of Tourette Syndrome and 
Chronic Tic Disorders. A Population-Based Cohort Study. JAMA Psychiatry 72, 787–793.
17 
McGrath, L.M., Yu, D., Marshall, C., Davis, L.K., Thiruvahindrapuram, B., Li, B., Cappi, C., Gerber, G., 
Wolf, A., Schroeder, F.A., et al. (2014). Copy number variation in obsessive-compulsive disorder and 
tourette syndrome: a cross-disorder study. J. Am. Acad. Child Adolesc. Psychiatry 53, 910–919.
Mercati, O., Huguet, G., Danckaert, A., André-Leroux, G., Maruani, A., Bellinzoni, M., Rolland, T., 
Gouder, L., Mathieu, A., Buratti, J., et al. (2016). CNTN6 mutations are risk factors for abnormal auditory 
sensory perception in autism spectrum disorders. Mol. Psychiatry.
Nag, A., Bochukova, E.G., Kremeyer, B., Campbell, D.D., Muller, H., Valencia-Duarte, A.V., Cardona, J., 
Rivas, I.C., Mesa, S.C., Cuartas, M., et al. (2013). CNV analysis in Tourette syndrome implicates large 
genomic rearrangements in COL8A1 and NRXN1. PLoS One 8, e59061.
Ogawa, J., Kaneko, H., Masuda, T., Nagata, S., Hosoya, H., and Watanabe, K. (1996). Novel neural 
adhesion molecules in the Contactin/F3 subgroup of the immunoglobulin superfamily: isolation and 
characterization of cDNAs from rat brain. Neurosci. Lett. 218, 173–176.
Pak, C., Danko, T., Zhang, Y., Aoto, J., Anderson, G., Maxeiner, S., Yi, F., Wernig, M., and Südhof, T.C. 
(2015). Human Neuropsychiatric Disease Modeling using Conditional Deletion Reveals Synaptic 
Transmission Defects Caused by Heterozygous Mutations in NRXN1. Cell Stem Cell 17, 316–328.
Robertson, M.M., Eapen, V., Singer, H.S., Martino, D., Scharf, J.M., Paschou, P., Roessner, V., Woods, 
D.W., Hariz, M., Mathews, C.A., et al. (2017). Gilles de la Tourette syndrome. Nat Rev Dis Primers 3, 
16097.
Sakurai, K., Toyoshima, M., Ueda, H., Matsubara, K., Takeda, Y., Karagogeos, D., Shimoda, Y., and 
Watanabe, K. (2009). Contribution of the neural cell recognition molecule NB-3 to synapse formation 
between parallel fibers and Purkinje cells in mouse. Dev. Neurobiol. 69, 811–824.
Scharf, J.M., Yu, D., Mathews, C.A., Neale, B.M., Stewart, S.E., Fagerness, J.A., Evans, P., Gamazon, 
E., Edlund, C.K., Service, S.K., et al. (2013). Genome-wide association study of Tourette’s syndrome. 
Mol. Psychiatry 18, 721–728.
Scharf, J.M., Miller, L.L., Gauvin, C.A., Alabiso, J., Mathews, C.A., and Ben-Shlomo, Y. (2015). 
Population prevalence of Tourette syndrome: a systematic review and meta-analysis. Mov. Disord. 30, 
221–228.
Schreiner, D., Nguyen, T.-M., Russo, G., Heber, S., Patrignani, A., Ahrné, E., and Scheiffele, P. (2014). 
Targeted combinatorial alternative splicing generates brain region-specific repertoires of neurexins. 
Neuron 84, 386–398.
Singh, S.K., Stogsdill, J.A., Pulimood, N.S., Dingsdale, H., Kim, Y.H., Pilaz, L.-J., Kim, I.H., Manhaes, 
A.C., Rodrigues, W.S., Jr, Pamukcu, A., et al. (2016). Astrocytes Assemble Thalamocortical Synapses 
by Bridging NRX1α and NL1 via Hevin. Cell 164, 183–196.
Sundaram, S.K., Huq, A.M., Wilson, B.J., and Chugani, H.T. (2010). Tourette syndrome is associated 
with recurrent exonic copy number variants. Neurology 74, 1583–1590.
Ushkaryov, Y.A., Petrenko, A.G., Geppert, M., and Südhof, T.C. (1992). Neurexins: synaptic cell surface 
proteins related to the alpha-latrotoxin receptor and laminin. Science 257, 50–56.
18 
Verkerk, A.J.M.H., Mathews, C.A., Joosse, M., Eussen, B.H.J., Heutink, P., Oostra, B.A., and Tourette 
Syndrome Association International Consortium for Genetics (2003). CNTNAP2 is disrupted in a family 
with Gilles de la Tourette syndrome and obsessive compulsive disorder. Genomics 82, 1–9.
Westfall, P.H., and Troendle, J.F. (2008). Multiple testing with minimal assumptions. Biom. J. 50, 745–
755.
de Wit, J., and Ghosh, A. (2016). Specification of synaptic connectivity by cell surface interactions. Nat. 
Rev. Neurosci. 17, 22–35.
Ye, H., Tan, Y.L.J., Ponniah, S., Takeda, Y., Wang, S.-Q., Schachner, M., Watanabe, K., Pallen, C.J., 
and Xiao, Z.-C. (2008). Neural recognition molecules CHL1 and NB-3 regulate apical dendrite orientation 
in the neocortex via PTP alpha. EMBO J. 27, 188–200.
Willsey, J.,  et al., 2017, Neuron 94, 1–14 May 3, 2017 http://dx.doi.org/10.1016/j.neuron.2017.04.024
19 
FIGURE LEGENDS 
Figure 1. Flow chart of experimental procedures and analyses. CNVs were called from genome-wide 
SNP genotype data generated from 2,434 TS cases and 4,093 controls (grey). Data processing, CNV 
detection and quality control steps (blue) are described in the STAR Methods. An outline of the main 
analyses are presented in red. Figures or tables relevant to each outlined step are in parentheses.  
Figure 2. Rare CNV burden in 2,434 TS cases and 4,093 controls.  
(A) The global burden of all rare (<1% frequency) CNVs > 30kb is shown for genic (top) and non-genic 
(bottom) CNVs and stratified by CNV type (all, loss (deletions), gain (duplications)). Global CNV burden 
is compared using three different metrics: 1) CNV Count, total number of CNVs per subject; 2) CNV 
length, aggregate length of all CNVs (in Mb); 3) CNV gene count, number of genes spanned by CNVs. 
Control rate, averaged baseline burden metric per control subject. Red boxes, odds ratios (box size is 
proportional to standard error); Blue lines, 95% confidence intervals. Genic CNVs are defined as those 
that overlap any exon of a known protein-coding gene. 
(B) Analyses in (A) were assessed further by partitioning CNV length burden of all CNVs (deletions + 
duplications) into different CNV size categories. Whiskers represent 95% confidence intervals. 
(C) The analysis in (B) was repeated for CNVs binned by frequency. 
Odds ratios (OR) were calculated from logistic regression analyses adjusted for covariates (see STAR 
Methods) using standardized burden metrics to allow for comparison. ORs >1 indicate an increased TS 
risk. P-values are derived from the likelihood ratio test. 
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Figure 3. Large, singleton CNVs and known pathogenic variants are overrepresented in TS.
(A) CNV count burden restricted to singleton events, stratified by CNV size and type 
(deletion/duplication). (B) CNV burden of all rare CNVs, separated by clinical relevance (benign, 
uncertain, pathogenic) according to the American College of Medical Genetics guidelines. ORs > 1 
represent an increase in risk for TS per CNV. P-values are derived from the likelihood ratio test. 
Figure 4. Segmental and gene-based tests converge on two distinct loci significantly enriched in 
TS cases.  
(A) Manhattan plot of segmental association test results representing genome-wide corrected p-values 
calculated at each CNV breakpoint. The two genome-wide significant association peaks correspond to 
deletions at NRXN1 (Plocus=7.0x10
-6, Pcorr=1.0x10
-3) and duplications at CNTN6 (Plocus=5.4x10
-5, Pcorr
=6.9x10-3). Red and blue levels correspond to a genome-wide corrected ɑ of 0.05 and 0.01, respectively.
(B) Heterozygous exonic deletions in NRXN1 found in 12 cases (0.49%) and 1 control (0.03%), 
corresponding to an OR=20.2, 95% CI (2.6-155.2). Exon-affecting CNVs cluster at the 5’ end with 
deletions across exons 1-3 found in 10 cases and no controls. Red, deletions in TS cases; Dark red, 
deletion in controls; Blue, case duplication. 
(C) Exon-spanning duplications over CNTN6 found in 12 cases and 2 controls (OR=10.2, [2.0-17.8]) 
CNTN6 duplications are considerably larger in cases compared to controls (640 vs. 143 kb, on average). 
Blue, case duplications; Dark blue, control duplications; Red, case deletion; Dark Red, control 
duplication. 
Table S1. Sample genotyping and QC summary 
Table S1A: Studies and genotyping
GENOTYPING BATCH ARRAY CENTER PHENOTYPES
CC OmniExpress v 1.0 Cardiff Control
CNP OmniExpress v 1.0 Broad Control/Clinical
GPC OmniExpress v 1.0 Broad Control/Clinical
WTCCC2 OmniExpress v 1.0 Cardiff Control
GGRI1 OmniExpress Exome v 1.1 UCLA Control/TS
GGRI2 OmniExpress Exome v 1.1 UCLA Control/TS
GGRI3 OmniExpress Exome v 1.1 UCLA Control/TS
Table S1B: QC summary
QC STEP CC CNP GPC WTCCC2 GGRI1 GGRI2 GGRI3 TOTALS
Initial Samples 1,146 1,511 3,197 960 1,152 2,160 136 10,262
Pre-cluster QC 1,141 1,510 3,126 870 1,148 2,152 135 10,082
Duplicate/Control Samples 1,141 1,491 3,081 870 1,134 2,143 134 9,994
Clinical Phenotype 1,141 1,312 1,388 870 1,134 2,143 134 8,122
Sex Concordance 1,141 1,312 1,387 870 1,132 2,140 134 8,116
Heterozygosity 1,138 1,247 1,301 859 1,107 2,089 133 7,874
Cryptic Relatedness 1,135 1,222 1,264 852 1,100 2,067 132 7,772
Intensity QC 1,101 1,106 1,164 832 1,014 1,843 119 7,179
EU Ancestry 1,067 634 1,143 813 959 1,803 116 6,535
CNV Load QC 1,067 634 1,141 808 958 1,803 116 6,527
Table S1
Table S2: GMM-based genotype calls at common CNV loci 
CNV_ID CLUSTER CLUSTER_LRR GMM_COPY CTRL_CALLS CASE_CALLS CTRL_FREQ CASE_FREQ p-value
HM3_CNP_134 1 -13.17478812 0 7 4 0.002 0.002 1.0
HM3_CNP_134 2 -1.544234008 1 296 191 0.072 0.078 0.4
HM3_CNP_156 1 -1.141264855 1 517 315 0.126 0.129 0.7
HM3_CNP_156 2 -10.96495207 0 18 13 0.004 0.005 0.6
HM3_CNP_299 1 -2.148959932 1 275 142 0.067 0.058 0.2
HM3_CNP_299 2 -20.27406193 0 4 3 0.001 0.001 0.7
HM3_CNP_369 1 2.201328191 3 234 137 0.057 0.056 0.9
HM3_CNP_494 1 -2.7402128 1 196 100 0.048 0.041 0.2
HM3_CNP_494 2 -23.74078464 0 1 1 0.000 0.000 1.0
HM3_CNP_540 1 1.648736036 3 392 263 0.096 0.108 0.1
HM3_CNP_540 2 -3.301784945 1 32 17 0.008 0.007 0.8
HM3_CNP_618 1 -3.470922513 1 44 24 0.011 0.010 0.8
HM3_CNP_618 2 1.817743156 3 167 91 0.041 0.037 0.5
HM3_CNP_655 1 -3.645609914 1 45 34 0.011 0.014 0.3
HM3_CNP_692 0 -4.175170396 1 10 11 0.002 0.005 0.2
HM3_CNP_692 2 2.34262532 3 47 32 0.011 0.013 0.6
HM3_CNP_803 1 -10.64502833 0 15 14 0.004 0.006 0.2
HM3_CNP_803 2 -1.347106673 1 417 258 0.102 0.106 0.6
HM3_CNP_850 1 -31.82000658 0 1 1 0.000 0.000 1.0
HM3_CNP_850 2 -2.649145422 1 74 49 0.018 0.020 0.6
HM3_CNP_850 3 1.410233747 3 165 101 0.040 0.041 0.8
Table S2
Table S3. Sensitivity analysis of HMM-based segmentation calls. 
Table S3A: Sensitivity analysis by locus 
CNV_ID CNV_TYPE GMM_TOTAL GMM_CTRL GMM_CASE HMM_CTRL HMM_CASE CTRL_SENSE CASE_SENSE p-value
HM3_CNP_134 DEL 498 303 195 300 194 0.99 0.995 1.0
HM3_CNP_156 DEL 863 535 328 531 321 0.993 0.979 0.11
HM3_CNP_299 DEL 424 279 145 279 145 1.000 1.000 1.0
HM3_CNP_369 DUP 371 234 137 208 122 0.889 0.891 1.0
HM3_CNP_494 DEL 298 197 101 197 101 1.000 1.000 1.0
HM3_CNP_540 DUP 655 392 263 391 261 0.997 0.992 0.57
HM3_CNP_540 DEL 49 32 17 32 17 1.000 1.000 1.0
HM3_CNP_618 DEL 68 44 24 44 24 1.000 1.000 1.0
HM3_CNP_618 DUP 258 167 91 166 90 0.994 0.989 1.0
HM3_CNP_655 DEL 79 45 34 45 34 1.000 1.000 1.0
HM3_CNP_692 DEL 21 10 11 10 11 1.000 1.000 1.0
HM3_CNP_692 DUP 79 47 32 47 32 1.000 1.000 1.0
HM3_CNP_803 DEL 704 432 272 428 272 0.991 1.000 0.16
HM3_CNP_850 DEL 125 75 50 75 50 1.000 1.000 1.0
HM3_CNP_850 DUP 266 165 101 164 98 0.994 0.970 0.15
Table S3B: Overall sensitivity across common CNVs 
CNV_TYPE GMM_TOTALS GMM_CTRL GMM_CASE HMM_CTRL HMM_CASE CTRL_SENSE CASE_SENSE p-value
DEL+DUP 4758 2957 1801 2917 1772 0.986 0.984 0.53
DEL 3129 1952 1177 1941 1169 0.994 0.993 0.81
DUP 1629 1005 624 976 603 0.971 0.966 0.65
Table S3C: Group-wise sensitivity analysis across individuals
CNV_TYPE CTRL_SENSE Std. Error CASE_SENSE Std. Error p-value
DEL+DUP 0.989 0.002 0.983 0.003 0.15
DEL 0.996 0.001 0.991 0.002 0.14
DUP 0.973 0.005 0.967 0.007 0.46
Table S3
Table S5: Clinical phenotypes of NRXN1 and CNTN6 CNV carriers 
Sample ID Gene Chr Start End Type Length Variant 
Effect
OCD ADHD Atypical Notes
TS1_0630 NRXN1 2 50821559 51021488 DEL 199.9 CODING N N Y Unspecified 
Developmental Delay 
(ICD-9: 315.9)
TS1_0180 NRXN1 2 50930181 51272375 DEL 342.2 CODING N N Y Asperger Syndrome
TS1_0446 NRXN1 2 50945471 51770480 DEL 825 CODING Y Y N
TS1_0105 NRXN1 2 51002606 51316822 DEL 314.2 CODING N Y N
TS2_1256 NRXN1 2 51028662 51458570 DEL 429.9 CODING N Y Y Other developmental 
speech or language 
disorder (ICD-9: 315.39)
TS2_0026 NRXN1 2 51041472 51483528 DEL 442.1 CODING N N N
TS2_0924 NRXN1 2 51041603 51528298 DEL 486.7 CODING N Y N
TS2_0750 NRXN1 2 51058745 51252137 DEL 193.4 CODING Y Y Y Asperger Syndrome
TS2_1238 NRXN1 2 51077569 51458570 DEL 381 CODING Y N Y Paranoid personality 
disorder
TS1_0573 NRXN1 2 51079482 51357902 DEL 278.4 CODING NA NA NA
TS1_0776 NRXN1 2 51101583 51308895 DEL 207.3 CODING N Y N Brother with Asperger 
Syndrome
TS1_0698 NRXN1 2 51123048 51286169 DEL 163.1 CODING Y Y N
TS2_1805 CNTN6 3 565961 1350458 DUP 784.5 CODING Y NA N
TS2_1405 CNTN6 3 668832 1143424 DUP 474.6 5' UTR Y Y N
TS2_1624 CNTN6 3 707257 1781739 DUP 1074 CODING N N N
TS2_1525 CNTN6 3 857325 1427769 DUP 570.4 CODING Y Y N
TS2_1568 CNTN6 3 864513 1425997 DUP 561.5 CODING Y Y N
TS2_1545 CNTN6 3 864513 1427769 DUP 563.3 CODING N Y N
TS2_1320 CNTN6 3 946290 1276092 DUP 329.8 CODING Y N N
TS1_0618 CNTN6 3 1125605 1315900 DUP 190.3 CODING N N N
TS2_1156 CNTN6 3 1218279 2170519 DUP 952.2 CODING N Y N
TS1_0558 CNTN6 3 1218279 2170519 DUP 952.2 CODING N Y N
TS2_0827 CNTN6 3 1226953 2170519 DUP 943.6 CODING N N N
TS2_0452 CNTN6 3 1260932 1556680 DUP 295.7 CODING N N N
Table S5
SNP genotyping 
SNP-based QC 
(Figure S1 and Table S1) 
Intensity-based QC 
(Table S1)
Rare CNVs 
9,375 CNV calls (Table S4)
CNV calling 
PennCNV + QuantiSNP 
Association testing Burden analysis 
Sensitivity assessment 
(Figure S2, Tables S2 and S3) 
In-silico validation 
(Figure S3) 
2,434 cases / 4,093 controls 
Illumina OmniExpress Array 
(Table S1) 
Genic CNVs (Fig 2) 
Singleton CNVs (Fig 3A) 
Clinically relevant CNVs (Fig 3B)  
Segmental test (Fig 4A) 
Gene-based test (Fig 4B and 4C) 
Carrier phenotypes (Table S5)  
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SUPPLEMENTAL INFORMATION 
Supplemental Figures 
Figure S1. SNP-based quality control and ancestry determination (related to Figure 1). (A) 
Exclusion of sample outliers based on heterozygosity, mean +/- 1.5 SD (red dotted lines). (B) 
Exclusion of non-European samples based on ethnicity estimation using fastStructure with 
HapMap continental groups and K=3 clustering. Samples with > 9.85% non-EU ancestry were 
excluded. This threshold was calibrated against the maximum of reference HapMap/1000 
Genomes European groups CEU, GBR, and TSI. The results of principal component (PC) 
analysis for the cohort and reference groups are plotted along (C) PCs 1 and 2 and (D) PCs 2 
and 3. Retained samples and excluded samples are shown in cyan and pink, respectively. CEU, 
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Utah residents with Northern and Western European ancestry from the CEPH collection; CHB, 
Han Chinese in Beijing, China; CHS, Southern Han Chinese; FIN, Finnish in Finland; GBR, 
British in England and Scotland; JPT, Japanese in Tokyo, Japan; LWK, Luhya in Webuye, 
Kenya; TSI, Toscani in Italia; YRI, Yoruba in Ibadan, Nigeria. 
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Figure S2. Gaussian mixture model (GMM) clusters of common HapMap3 CNVs (related 
to Figure 1, Table S2 and S3). (A) A representative GMM cluster plot for locus 
HM3_CNP_540. Subplots for each CNV depict, counter-clockwise: the best-fit model, Akaike 
and Bayesian Information Criterion metrics calculated for GMM fitting 1-9 components, and the 
posterior probability for CNV cluster assignment (colored lines) overlaying the distribution of 
median summarized intensity values for all samples across region calculated using the best-fit 
model. (B) GMM plots for the 10 additional HapMap3 CNV loci that were used to critically 
evaluate sensitivity between cases and controls (STAR Methods, Table S2 and S3). 
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Figure S3. In silico validation of CNV calls (related to Figure 1). (A) Representative CNVs 
scored with various CNV validation metrics. Abbreviations (see STAR Methods for details): 
median summarized intensity measures across a putative CNV locus, standardized by sample 
(LRR-Z), proportion of probes with a B Allele Frequency (BAF) banding pattern indicative of a 
duplication event (BAF-D), proportion of samples with LRR-Z scores indicative of a polymorphic 
event (OUTLIER-Z). (B) Distribution of median summarized standardized intensity values (LRR-
Z) for validated CNVs derived from HapMap samples generated on identical arrays as used in 
this study (Illumina OmniExpress). Based on this distribution, CNVs without an LRR-Z score < 
SAMPLE_ID CHR BP1 BP2 COPY #SNPS START_SNP END_SNP LRR-Z BAFdel BAFdup OUTLIER-
Z
CNP_0348 6 67801176 67887156 1 21 rs9363696 rs16899159 -2.96 0.62 0.38 0.00015
CNP_0348
1
6 67907952 68586809 1 120 rs12197620 rs9354637 -2.9 0.76 0.16 0.00015
CNP_0348 6 68707131 69142008 1 96 rs4707250 rs9363918 -2.93 0.73 0.17 0.00015
WT_0533
2
10 47375657 47703869 3 48 rs28599894 rs4434935 2.48 0.33 0.63 0.09
CC_0852 10 47375657 47703869 3 48 rs28599894 rs4434935 2.36 0.33 0.60 0.09
WT_0866 10 47375657 47703869 3 48 rs28599894 rs4434935 2.33 0.38 0.60 0.09
TS_0457 10 47375657 47703869 3 48 rs28599894 rs4434935 2.29 0.39 0.60 0.09
TS_1843 10 47375657 47703869 3 48 rs28599894 rs4434935 2.05 0.39 0.60 0.09
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2.3 (deletions) and > 1.3 (duplications) were flagged for manual inspection. (B) Example of a 
large singleton mosaic event flagged for exclusion in sample CNP_0348, indicated as (1) in 
Figure S3A. This CNV on chromosome 6 was detected as three separate CNVs after taking the 
consensus of two different HMM calling algorithms. The largest CNV call exhibits an LRR-Z 
score of -2.86 (left, red arrow), indicative of a deletion, but shows a clear BAF-banding pattern 
of a duplication event (right), with a BAFdup score of 0.16. This is indicative of a mosaic event, 
where only a proportion of cells from sample CNP_0348 harbor the deletion event. (C) Example 
of a polymorphic CNV on chr10:47,375,657-47,703,869 misclassified as a rare event due to 
reduced sensitivity, indicated as (2) in Figure S3A, with an OUTLIER-Z score of 0.09. 
Genotyping using GMM-based clustering indicated that this misclassified rare event (MAF < 
0.01) has a MAF of 0.12. 
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Figure S4. Elevated CNV burden is consistent across datasets (related to Figure 2).  We 
assessed for increased CNV burden using different metrics and found that total CNV length was 
most significantly associated with an increased risk for TS (Figure 2).  To ensure that the 
enrichment signal was not driven by a single dataset, here we repeated the assessment of 
burden by total CNV length, examining all TS samples compared to each of the control sample 
sets individually and to all control samples together.  An increased burden is consistent across 
all datasets, and additionally when stratified by CNV type: loss (deletions); gain (duplications) 
and loss + gain (both deletions and duplications). GGRI, controls collected and genotyped 
alongside TS cases; Cardiff, CNP, USC, WTCC, control samples taken from external datasets, 
as defined in Table S1A and STAR Methods. 
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Figure S5. Exonic CNVs affecting NRXN1 (related to Figure 4). UCSC genome browser 
track depicting all exonic NRXN1 CNVs > 50kb identified in this study: 12 heterozygous case 
deletions (red), one control deletion (dark red) and a single case duplication (blue). Probe-level 
plots of Log R Ratio (LRR) intensity and B Allele Frequency (BAF) for all exonic NRXN1 CNV 
carriers shown in the same order as the UCSC genome browser track. Colored probes indicate 
the location of called deletions (red) and duplications (blue). 
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Figure S6. CNVs overlapping CNTN6 (related to Figure 4). UCSC genome browser track 
displaying heterozygous genic duplications in TS cases (blue) and controls (dark blue) followed 
by deletions (red). Probe-level LRR and BAF plots for all 16 CNVs detected spanning CNTN6
are shown below the genome browser schematic. CNV carriers are shown in the same order as 
the UCSC genome browser track. Colored probes indicate the location of called deletions (red) 
and duplications (blue). 
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Figure S7. Examination of genome-wide TS case-control CNV analysis for population-
specific effects (related to Figure 4). To verify the robustness of our results to population 
stratification, we pair-matched each case subject with exactly one control such that the global 
difference between all pairs is minimized using SpectralGEM. (A) The SNP-based λgc of the 
resultant dataset (1996 cases and 1996 controls) was an acceptable 1.082. Manhattan plots of 
segmental association results demonstrate that (B) deletions in NRXN1 and (C) duplications in 
CNTN6 are significant with an ɑ < 0.05 (blue line). Deletions and duplications were analyzed 
separately. The -log10 (p-value) displayed is empirically corrected for FWER (family-wise error 
rate) genome-wide using the max(T) method with 1,000,000 permutations. 
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Supplemental Tables 
Table S1. Sample genotyping and QC summary (related to Figure 1). (A) Summary of 
included studies and genotyping information. Sample phenotypes, genotyping platform, and 
genotyping center for different datasets collected for this study are shown, separated by study. 
(B) Summary of quality control procedures by study. The number of samples remaining within 
each batch after each successive quality control step (see STAR Methods) is shown. Study 
abbreviations: Cardiff Controls (CC), Consortium for Neuropsychiatric Phenomics (CNP), 
Genomic Psychiatry Cohort (GPC), Wellcome Trust Case-Control Consortium (WTCCC2) and 
TS cases and controls collected for this study (GGRI1-3). 
See attached tscnv_table-s1.docx
Table S2. Gaussian Mixture Model (GMM) clustered genotype calls at common Hapmap 3 
CNVs (related to Figure 1, Figure S2, and Table S3). For sensitivity analysis, all 6,427 
samples used in this study were genotyped across 11 common Hapmap3 CNVs using a locus-
specific GMM-based clustering method (see Supplementary Methods). The numbers for 
CNV_ID: Hapmap3 accession number. CLUSTER_ID: Arbitrary identifier assigned by the 
clustering algorithm. CLUSTER_LRR: The mean value of all median-summarized intensity 
values for all samples assigned to the cluster. CLUSTER_COPY: Copy-number state inferred 
by examination of raw LRR-intensity values for samples within the cluster. Call frequencies 
(FREQ) for 4,093 controls (CTRL) and 2,434 TS cases (CASE) reflect the proportion of GMM-
based genotype calls with >0.95 posterior probability of cluster assignment. There was no 
significant difference in CNV genotype frequency between phenotypic groups at any of the 21 
non-reference genotype calls across all 11 loci (Fisher’s exact test).
See attached tscnv_table-s2.docx
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Table S3. Sensitivity analysis of consensus Hidden Markov Modeling (HMM) 
segmentation calls (related to Figure 1, Figure S2, and Table S2). (A) Sensitivity by locus. 
The sensitivity of HMM calling was defined as the number of concordant HMM calls divided by 
the total number of non-reference genotypes called in the same individual by Gaussian Mixture 
Model (GMM) clustering. Non-reference GMM calls were collapsed into calls of the same class 
(CNV_TYPE, DEL or DUP). (B) Overall sensitivity across all loci. P-values for both individual 
and aggregated locus-specific locus-based tests were calculated using Fisher’s exact test. (C) 
Group-wise comparison of sensitivity between cases and controls based on the average 
sensitivity calculated within each individual. No significant difference in the average individual 
sensitivity was observed between phenotypic groups whether considering deletions, 
duplications, or both in concert (Welch’s t-test). 
See attached tscnv_table-s3.docx
Table S4. Rare CNV calls from 2,434 TS cases and 4,093 controls (related to Figures 1-4). 
This table contains a list of all rare CNVs detected in this study (STAR Methods). ID, sample ID; 
SEX, sample sex, Phenotype and comorbid disorders, TS, Tourette syndrome; OCD, 
obsessive-compulsive disorder; ADHD, attention deficit disorder; CHR, chromosome; START, 
CNV start (hg19 coordinates); STOP, CNV end; SIZE, CNV size in bp; TYPE, CNV copy-
number; SITES, number of SNP markers spanning CNV; FREQUENCY, CNV frequency; 
RSID_START, first SNP within the CNV; RSID_STOP, last SNP within the CNV; 
GENE_COUNT, number of genes spanned by CNV; GENE_SYMBOLS, genes spanned by 
CNV. GENE_COUNT and GENE_SYMBOLS are determined by overlap with exons of protein-
coding genes (STAR Methods). 
See attached tscnv_table-s4.xlsx
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Table S5. Clinical phenotypes of NRXN1 and CNTN6 CNV carriers. Clinical phenotypes for 
all CNV carriers of the two significant TS loci detected in this study: deletions at NRXN1 and 
duplications at CNTN6. ID, Sample ID; Gene: Gene locus; Chr, chromosome; Start, CNV start 
(hg19 coordinates); End, CNV end; Type, CNV type; Length,  CNV length (in kb); Variant Effect, 
CNV location within gene; Common comorbid disorders for TS, ADHD, attention deficit disorder; 
OCD, obsessive-compulsive disorder; Atypical, Case flagged for atypical presentation; Notes: 
Description of atypical phenotypic features.  NA, No clinical information available. 
See attached tscnv_table-s5.docx 
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STAR METHODS 
Sample Ascertainment
Tourette Syndrome (TS) cases were ascertained primarily from TS specialty clinics 
through sites distributed throughout North America, Europe and Israel as part of an ongoing 
collaborative effort by the Tourette Syndrome Association International Consortium for Genetics 
(TSAICG) as described in detail elsewhere (Scharf et al., 2013). Subjects were assessed for a 
lifetime diagnosis of TS, Obsessive Compulsive Disorder (OCD) and 
Attention-Deficit/Hyperactivity Disorder (ADHD) using a standardized and validated 
semi-structured direct interview (TICS Inventory) (Darrow et al., 2015; Tourette Syndrome 
Association International Consortium for Genetics, 2007). An additional 628 cases were 
collected at 9 TS specialty clinics in Austria, Canada, France, Germany, Greece, Hungary, Italy 
and the Netherlands by expert clinicians using Tourette Syndrome Study Group criteria for 
Definite TS (DSM-IV TS diagnosis plus tics observed by a trained clinician) as well as DSM-IV 
diagnostic criteria for OCD and ADHD, along with 610 ancestry-matched controls as described 
previously (Paschou et al., 2014). We did not conduct formal standardized assessments for 
other neurodevelopmental disorders (NDDs) such as Intellectual Disability/Developmental Delay 
(ID/DD), Autism Spectrum Disorder (ASD), or schizophrenia/childhood psychosis; however, 
participants and their parents were asked about the presence of established or suspected 
diagnoses. 
Additional TS case samples were obtained through web-based recruitment of individuals 
with a prior clinical diagnosis of TS who subsequently completed an online questionnaire that 
we have validated against the gold-standard TS structured diagnostic interview with nearly 
100% concordance for all inclusion/exclusion criteria as well as high correct classification rates 
for DSM-IV diagnoses of OCD and ADHD (Darrow et al., 2015; Egan et al., 2012). Individuals 
for web-based screening were solicited through the Tourette Association of America mailing list 
as well as from 4 TS specialty clinics in the United States. Individuals with a history of 
intellectual disability, seizure disorder, or a known tic disorder unrelated to TS were excluded. 
External Control Sets 
Additional control subjects were taken from four external large-scale genetic studies 
consisting of healthy individuals sampled from similar geographic locations, specifically selected 
because intensity data was available and generated on the same Illumina OmniExpress 
platform as the TS cases and controls collected as part of this study: 
1. Cardiff Controls (CC): UK Blood donors were recruited in Cardiff at the time of blood 
donation at centres in Wales and England. Although not explicitly screened for 
psychiatric disorders, these controls are likely to have low rates of severe 
neuropsychiatric illness, as blood donors in the UK are only eligible to donate if they are 
not taking any medications. 57% of these controls were male. Genotyping on the 
Illumina OmniExpress was performed at  
2. Consortium for Neuropsychiatric Phenomics (CNP): A collection of neuropsychiatric 
samples composed of patients with attention deficit hyperactivity disorder (ADHD), 
bipolar disorder (BD), schizophrenia (SCZ), and psychologically normal controls, 
collected throughout North America as part of a large NIH Roadmap interdisciplinary 
research consortia centered at the University of California, Los Angeles. Only the control 
samples were used in this study.  
3. Genomic Psychiatry Cohort (GPC) (Pato et al., 2013): A large, longitudinal, population 
resource composed of clinically ascertained patients affected with BD, SCZ, their 
unaffected family members, and a large set of control samples with no family history of 
either disorder. Samples were collected at various sites throughout North America in a 
National Institute of Mental Health-sponsored study lead by the University of Southern 
California. 
4. Wellcome Trust Case Control Consortium 2 (WTCCC2) (Power and Elliott, 2006): A 
subset of control samples from the National Blood Donors Cohort. 
Genotyping and data preprocessing
Cases and controls collected specifically for this study (GGRI) were all genotyped on the 
Illumina OmniExpress Exome v1.1, while the remaining control samples from the CC, CNP, 
GPC, and WTCCC2 cohorts were genotyped on the Illumina OmniExpress 12v1.0. The content 
of these two arrays is identical except for 1) exome-focused content on the former and 2) 
additional intensity-only markers on the latter. We have observed that exome-specific assays in 
general exhibit a much higher variance overall in their derived log-R ratio (LRR). Therefore, in 
order to avoid detection biases due to this differential variance as well as due to unequal probe 
coverage, only the SNP assays with common identifiers across all versions of the OmniExpress 
arrays used in all datasets were used for quality control (QC) and CNV detection, a total of 
689,077 markers. 
To ensure the generation of the most reliable SNP calls, intensity measures, and B-allele 
frequencies (BAF) and to reduce the effect of differential processing, a custom cluster file was 
generated for each dataset separately, and each genotype batch when such information was 
available. Since the performance of Illumina’s proprietary normalization and cluster generation 
process improves with the number of samples, we processed all of the raw intensity data 
available, regardless of clinical phenotype phenotype. An initial round of QC was carried out 
using Illumina Beeline to determine baseline calling rates for each sample using the canonical 
cluster file (*.egt) provided by the manufacturer for each array version. Any sample with a call 
rate < 0.98 or a log-R ratio (LRR) standard deviation > 0.30 was deemed a failed assay and 
removed (Pre-cluster QC, Supplementary Table 1B). SNP clustering and genotype calling was 
then performed in GenomeStudio with only passing samples within each dataset. 
Genotype sample QC 
We performed an initial round of QC based on SNP genotype data. All samples at this 
stage had a minimal call rate >0.98. For duplicate samples, we retained samples with the higher 
call rate. Additionally, we removed samples with with discordant sex status and excess 
autosomal heterozygosity rate (total sample mean +/- 1.5SD). We filtered autosomal SNPs for 
missingness > 0.01; minor-allele frequency > 0.01; deviation from Hardy-Weinberg equilibrium 
(P < 10^-6); and pruned SNPs for LD (r^2 < 0.05). We used a total of 62,104 SNPs for 
relatedness testing using PLINK. For all pairs of subjects with PI_HAT > 0.185, we removed one 
subject at random, with the exception that if a control individual was related to a subject with a 
neuropsychiatric phenotype, it was explicitly marked for removal. 
Genome-wide detection of CNV loci
We employed two widely-used HMM-based CNV calling algorithms, PennCNV (Wang et 
al., 2007) (version 2011-05-03, http://penncnv.openbioinformatics.org/en/latest/), and 
QuantiSNP (Colella et al., 2007) (version 2.0, 
https://sites.google.com/site/quantisnp/downloads), to initially detect structural variants in our 
dataset. We created GC-adjusted LRR intensity files for all samples using the GC-waviness 
correction method (Diskin et al., 2008). For PennCNV, a custom population B-allele frequency 
file was created for each dataset separately and CNV calls were generated using the standard 
protocol. QuantiSNP calls were similarly generated on the GC-adjusted intensity files. Using 
custom PERL scripts, a concordant callset between both CNV callers was then generated by 
taking the intersecting boundaries of overlapping calls of the same CNV type (deletion or 
duplication). Additionally, adjacent CNV calls were merged if they were spanned by a CNV 
called by the other HMM algorithm. As HMMs have been shown to artificially break up large 
CNVs, we also merged CNV segments in the final concordant callset if they were of the same 
copy number and the number of intervening markers between them was less than 20% of the 
total of both segments combined using the PennCNV’s “clean_cnv.pl” script. We repeated this 
joining process iteratively until no more merging of segments occurred. 
Array intensity sample QC 
The PennCNV calling algorithm generates a number of array intensity-based metrics 
with regard to CNV assay quality. Intensity-based QC was conducted based on the distribution 
of all available assays and subsequently combined with the results from the SNP-based QC. To 
remove samples with data unsuited for CNV detection, we used empirically defined thresholds 
across several different metrics:  
1. Waviness factor (WF) - measures the waviness in intensity values, a known artifact 
caused by improper DNA concentration that can lead to spurious calls.  
2. Log-R ratio standard deviation (LRR-SD) - a measure of the overall variance in intensity 
values. 
3. B-allele frequency drift standard deviation (BAF-SD) - the standard deviation of 
autosomal BAF values between 0.25 and 0.75.  
Thresholds for WF and LRR-SD were determined separately for each dataset by both manual 
examination of QC metrics and taking the mean + 3 x SD to determine outlying samples. As the 
LRR is essentially composed of the sum of allelic intensities, it is highly correlated with BAF-SD. 
Therefore, instead of a hard cutoff, we opted to remove outliers in BAF-SD while considering 
LRRSD. We plotted sample BAF-SD values ranked by LRR-SD and fit a loess curve using the R 
function loess.smooth, adjusting the span parameter until the distribution was adequately fit. We 
then shifted the fitted curve by an appropriate factor (typically about 1.2) to establish a cutoff for 
BAF-SD. This was done for each dataset separately. Following intensity-based QC, all samples 
had an LRR-SD of <0.24, absolute value of WF < 0.04, and an BAF-SD < 0.05, well within 
established limits required for reliable CNV detection. 
EU-ancestry estimation 
Following sample removal based on SNP and intensity-based QC, we removed all 
clinical non-TS samples from external studies, and genotype data for all remaining samples was 
subsequently combined with data from publicly available HapMap samples of European, 
African, and Asian continental ancestry (Illumina). All available European (EU) population 
samples from the 1000 Genomes Project were also included to establish an appropriate 
calibration threshold for EU ancestry designation. A randomly-thinned dataset comprised of 
19,024 LD-independent markers were used for ancestry inference using fastStructure with k=3, 
and samples were excluded if they contained > 0.0985 non-EU ancestry (Supplementary Figure 
1). A final round of ancestry exclusion was performed by removing all samples outside of the 
median +/- 3SD of the first three ancestry PCs.  
CNV load sample QC 
Although SNP and intensity-based QC removed most failed assays, we performed a final 
round of sample QC, removing eight additional samples with excessively high CNV load based 
on the total number of CNV calls (>45) or total CNV length (>10Mb). These thresholds were 
determined empirically by visual inspection of distributions across all datasets combined. Our 
final dataset after QC consisted 6,527 samples: 2,434 TS cases and 4,093 controls. 
Data handling and CNV visualization 
To facilitate further data processing and visualization of CNV events, we generated an 
HDF5 database consisting of sample metadata, CNV calls, probe information, LRR intensity and 
BAF values for all assays. Normalized intensity values were also generated by converting the 
GC-corrected, median-centered LRR measures into Z-scores within each sample and inserted 
into the database. Calculations for the sensitivity assessment (following section) were 
performed in Python. Visualization of GMM cluster plots (Figures S2A, S2B, S3C); median 
Z-score outlier detection (MeZOD) CNV calls (Kirov et al., 2012) (Figure 3B); and probe-level 
CNV plots (Figures S5 and S6) were generated from Z-scores of intensity data using in 
Matplotlib. 
Sensitivity assessment
We augmented a previously described method (Vacic et al., 2011) to investigate whether 
any difference in sensitivity to detect CNVs existed between cases and controls within the 
context of our study. Both HMM-based CNV callers we employed for genome-wide detection are 
univariate methods completely agnostic of intensity information across multiple samples and do 
not use known population frequency prior probabilities in their calling algorithms. Therefore, 
common CNVs act as an ideal proxy to evaluate the effectiveness to detect rare events 
accurately; they are detected in the same manner but are present at much higher frequencies, 
enabling an accurate estimation of the overall sensitivity of detection for rare events 
genome-wide. 
We used the UCSC Genome Browser (https://genome.ucsc.edu) liftOver tool to translate 
a list of common HapMap3 CNVs to the hg19 reference. To match the thresholds used for our 
association tests in this study, we filtered the list of common CNVs to those that were >30 kbp in 
length. We reduced the number of markers required slightly to a minimum of 9 to ensure that an 
adequate number of events could be assessed. For each common CNV meeting these criteria, 
we examined the distribution of median-summarized normalized intensity measures within the 
CNV region across all study samples and retained only those loci that displayed no evidence of 
clustering intro different copy-number states. A total of 11 common CNV loci were retained for 
sensitivity analysis (Figure S2 and Table S2). 
We generated locus-specific genotyping calls in the following manner. First, we extracted 
the LRR intensity Z-scores for all probes in the region across all samples. The Z-scores for all 
probes spanning the CNV locus were then subjected to second round of normalization across 
all samples. A Gaussian mixture model (GMM) was fit to this distribution of Z-scores using the 
SciKit-learn Python package. The optimum number of clusters was automatically determined by 
minimization of the Bayesian Information Criterion (BIC) and corrected, when necessary, by 
manual adjustment. Individuals were assigned to a cluster only if the posterior probability of 
assignment exceeded 0.95.  
Copy number state was inferred by examining the original LRR intensity values for 
samples within each cluster. We inspected for allele frequency differences between controls and 
cases for all clusters and found no significant difference (Fisher Exact Test, Table S2). We 
collapsed the clusters at each locus into CNVs of the same type (deletion or duplication), and, 
as this locus-specific genotyping method is more sensitive than HMM segmentation methods, 
we used the proportion of concordant of HMM-based calls as a measure of segmentation 
detection sensitivity. We found no significant difference in sensitivity to detect common CNVs 
between phenotypic groups at any of the 11 loci tested, either independently, or in concert 
(Fisher Exact Test, Supplementary Table S3A and S3B). Furthermore, the mean sensitivity for 
each sample was calculated and collectively assessed for any systematic difference between 
phenotypic groups. Considering duplications, deletions, or both in concert, we observed no 
significant difference in the sensitivity of segmentation calls between case and control groups 
(Wald T-test, Supplementary Table S3C). 
Determination of rare CNVs 
Calls were removed from the dataset if they spanned less than 10 markers, were less 
than 30kb in length, or overlapped by more than 0.5 of their total length with regions known to 
generate artifacts in SNP-based detection of CNVs. This included immunoglobulin domain 
regions, segmental duplications, and regions that have previously demonstrated associations 
specific to Epstein-Barr virus immortalized cell lines (Shirley et al., 2012). In addition, we 
removed calls that spanned telomeric (defined as 100kb from the chromosome ends), 
centromeric regions, and gaps in the reference genome. We assigned all CNV calls a specific 
frequency count using the PLINK command `--cnv-freq-method2 0.5`. Here, the frequency count 
of an individual CNV is determined as 1 + the total number of CNVs overlap by at least 50% of 
its total length (in bp), irrespective of CNV type. We then filtered our callset for CNVs with MAF 
< 1% (a frequency of 65 or lower across 6,527 samples). Furthermore, we removed calls if they 
overlapped by more than 50% of their length to common CNVs regions determined by several 
high-quality, publically available SNP-array datasets: 
1. 845 population samples from the Deciphering Developmental Disorders study (compiled 
by DECIPHER ) 1
2. 450 population samples from the 42M genotyped study (compiled by DECIPHER) 
3. 5919 population samples from the Affy6 study (compiled by DECIPHER) 
1 https://decipher.sanger.ac.uk/index 
Conservatively, CNVs regions were considered common if present at a frequency of >10% 
within any individual dataset above. 
In-silico validation 
For each putative rare CNV, we generated two different metrics based on intensity and 
B-allele frequency (BAF) banding. To qualifying CNVs based on intensity, we adopted a 
methodology similar to the MeZOD method described elsewhere (Kirov et al., 2012), with 
modification. We observed that standardized intensity measures typically range from < -20 for 
homozygous deletions, [-6,-2.3] for heterozygous deletions, and > 1.3 for duplications. Because 
of the disproportionately large effect on intensity measures caused deletions events, performing 
a second round of normalization across all samples within each putative CNV will skew the 
overall distribution when homozygous deletion events are present. Therefore, we only 
performed a single round of normalization of LRR intensity measures, within each sample. Each 
CNV was scored by calculating the median of LRR intensity Z-scores (LRR-Z) for all probes 
within the region. To qualify CNVs based on BAF banding, we calculated the proportion of 
probes within the CNV region that showed evidence of a duplication event (BAF of [0.25-04] or 
[0.6-0.8]), and denoted this measure “BAF-D.”  
Based on examination of our own data, as prior observations (Sanders et al., 2015) we 
flagged deletions that had a LRR-Z > -2 or BAF-D > 0.02, and duplications with a LRR-Z < 1 or 
BAF-D < 0.1. To avoid differential missingness caused by subtle differences between arrays, we 
did not impose any hard cutoff for CNV exclusion based on these metrics. These thresholds 
were applied to flag CNV calls with marginal scores for manual inspection and the removal 
obviously misclassified events. Through this in-silico validation process we discovered multiple 
instances of CNV calls likely due to individual mosaicism (Figure S3A and S3B), and removed 
these events from subsequent analysis.  
Furthermore, for each rare CNV call, we used distribution of summarized intensity 
information across all individuals For each rare CNV region, we quantified proportion of samples 
whose LRR-Z metric fell outside of [-2.3, 1.3] and further inspected these regions manually. 
Putative rare CNV loci that showed substantial evidence for extensive polymorphism were 
subsequently scored for frequency using the GMM genotyping method described above (Figure 
S3C) and conservatively, only removed if shown to be variant in more than 10% of the samples 
across the entire dataset.
Annotation of rare cnvs 
Rare CNVs were annotated for gene content according to RefSeq provided by the hg19 
assembly of the UCSC Genome Browser. We only considered a CNV as “genic” if it overlapped 
any exon of a known protein-coding transcript (as designated by the RefSeq transcript 
accession prefix “NM”). The “gene count” of a CNV represents the total number of 
non-redundant genes whose respective transcripts it overlaps. “Non-genic CNVs” represent all 
variants that are not genic according to the definition above. In addition, all rare CNVs were 
assessed for clinical relevance in accordance with guidelines set forth by the American College 
of Medical Genetics (ACMG). This was accomplished through the use of the Scripps Genome 
Advisor (SGA) (https://genomics.scripps.edu/ADVISER/); inspection of curated resources 
including ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), DECIPHER 
(https://decipher.sanger.ac.uk/index), and Online Mendelian Inheritance in Man 
(https://www.omim.org/); and followed by confirmation through review of primary literature. 
Conservatively, we only considered a CNV as “pathogenic” if directly supported by more than 
one primary publication. To screen for additional relevant pathogenic variants, we screened for 
variants that overlapped compiled lists defined in the literature (Malhotra and Sebat, 2012; 
McGrath et al., 2014). All non-pathogenic variants were automatically annotated by SGA: those 
classed as Category 2-4 were assigned as a variant of “unknown clinical significance”, and 
those assigned to Category 5 were considered “benign”. Note that, as only rare CNVs were 
considered, the number of “benign” variants is small. 
Global CNV burden analysis
We measured global CNV burden using three separate metrics: the number of rare 
CNVs (CNV count), the total length of all CNVs (CNV length) and the total number of genes 
intersected by CNVs (CNV gene count). To examine the effect of different covariates on our 
different metrics of global CNV burden, we first fit a linear regression model for each burden 
metric, using the glm function in R: 
Burden_metric ~ TS_status + subject_sex + LRR_SD + ancestry_PCs 
In the above model, as assay intensity quality metrics are highly correlated, we utilized LRR_SD 
as a single measure of assay quality, and ancestry_PCs include the first ten principal 
components (PCs) of ancestry derived from SNP data. Of the above included covariates 
(excluding TS_status), under any metric considered, only LRR_SD, PC1, and PC2 were 
significant predictors of global CNV burden (P<0.05). To assess for a global burden difference 
between TS cases and controls, we fit a logistic regression model in R:  
TS_status ~ Burden_metric + subject_sex + LRR_SD + PC1 + PC2 + PC3 + PC4 
Independent variables included burden metric, subject sex, LRR_SD, and, to correct for 
potential population stratification associated with the case-control status, the first four ancestry 
PCs. We note that our logistic model includes all covariates that were found to be significantly 
associated with global CNV burden as determined by linear regression described above. ORs 
above 1 indicate an increased risk for TS per unit of CNV burden and P-values were calculated 
using the likelihood ratio test. In Figure 2, global burden was analyzed separately for genic 
CNVs and non-genic CNVs. Since we were interested in comparing the relative contribution to 
TS risk by different measures of burden and across various categories, sizes, and frequency 
classes, the ORs presented in Figure 2 and Figure S4 are calculated from standardized CNV 
burden metrics. In Figure 3, we calculated OR using the unstandardized value of actual CNV 
counts, as this is directly interpretable. 
CNV burden of evolutionarily conserved genes  
Rare genic CNVs were annotated using pLI (probability of LoF Intolerance) scores 
(http://exac.broadinstitute.org/). A CNV was marked as “constrained” if it overlapped any exon of 
a gene with a pLI score of > 0.9, as per the approach by Ruderfer and colleagues (Ruderfer et 
al., 2016). To examine whether such constrained CNVs are enriched in TS patients, we 
assumed a Poisson distribution of such rare events, and conducted a Poisson regression with 
adjustment of subject sex, LRR_SD, the first four ancestry PCs: 
Constrained_CNVs ~ TS_status + subject_sex + LRR_SD + PC1 + PC2 + PC3 + PC4
We tested the large (>1Mb), singleton CNVs that affect conserved genes (pLI>0.9) stratified by 
CNV type, and compared the relative risk of such events to all large, singleton genic CNVs. 
Locus-specific tests of association 
The segmental test of association was performed by quantifying the frequencies of case 
and control CNV carriers at all unique CNV breakpoint locations; the unique set of CNV 
breakpoints defines all locations genome-wide where the frequency of CNVs can differ between 
cases and controls. For gene-based association tests, we restricted our analysis to genic CNVs 
(CNVs that intersect an exon of any protein-coding transcript, as defined above) and quantified 
the frequencies of cases and control CNVs across each gene. Locus-specific p-values for both 
tests of association were determined by 1,000,000 permutations of phenotype labels, and 
genome-wide corrected p-values were obtained using the max(T) permutation method as 
implemented in PLINK v1.07, which controls for family-wise error rate by comparing the 
locus-specific test statistic to all test statistics genome-wide within each permutation. 
Association tests were conducted separately for deletions and duplications.  
Sensitivity analysis of association results
The segmental association test after carefully pair-matching each case with a control 
such that the global difference between each pair was minimized using SpectralGEM (Lee et al., 
2010) (Figure S6). For the matched segmental association analysis, because of the drastic 
reduction in sample size, a genome-wide corrected alpha < 0.05 was used as a cutoff to 
indicate significance.  
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